Benefit — CDER stance
What Snapshot-grade context-of-use evidence saves in Type B/C stance
Type B/C meeting stance is set by the paper on file. Independent context-of-use + ongoing-evaluation evidence reshapes the reviewer's opening question from "do you monitor this AI?" to "here is the record."
The three moments where it matters
- Type B meeting (End-of-Phase-2 / pre-Phase-3). Reviewer asks about AI-in-trial context of use. Independent evidence lets the sponsor answer with a validated record.
- Type C meeting (specific topic). AI-related Type C requests are climbing 2024-2026. Preparation lands cleaner with an independent monitoring record.
- Pre-NDA / pre-BLA discussion. Reviewer applies context-of-use lens to every AI-touched surface. Snapshot maps directly onto that lens.
Dollar frame
Meeting-response cycle cost: a serious AI-related reviewer follow-up cycle typically runs $250K-$1.5M in Reg Affairs + biostats + external counsel time per round.
Program-delay cost: a meeting that adds even three months to program timeline can cost $25M-$150M in lost exclusivity terms.
Preventive discipline cost: $499 for context-of-use documentation on the actual trial-AI surface.
Who at your org cares
- VP Regulatory Affairs — Type B/C meeting stance
- Chief AI Officer — context-of-use inventory + governance
- Head of Clinical Development — program-timeline defense
- Chief Quality Officer — ongoing-evaluation SOP fit
What "having it" looks like
Green: Snapshot on file. Context of use named + evaluated. Reviewer conversation opens with the sponsor on the front foot.
Red: AI mentioned in briefing book, no ongoing-evaluation record on file. Reviewer's first question triggers the follow-up round.
$499. 3 business days.
Context-of-use documentation + ongoing-evaluation evidence for the actual trial-AI surface CDER cares about.
Buy $499